Img Alt - Mobile header
Back

Prof. Joseph Zohar

Prof. Joseph Zohar

Israel

Director of the National Post-Trauma Center, Research Foundation by the Sheba Medical Center, Israel.

Professor Zohar is an Emeritus Professor of Psychiatry at the Faculty of Medicine, Tel Aviv University. He is also the President-Elect of the International College of Neuropsychopharmacology (CINP) and Past-President of the European College of Neuropsychopharmacology (ECNP).

Professor Zohar founded and chairing the task force of Neuroscience based Nomenclature (NbN). He also founded the Israeli consortium on PTSD, and the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). Prof. Zohar is also a board member of the International Master in Affective Neuroscience and member of the European Group for Study of Resistant Depression (GSRD).

He has authored over 400 papers and authored or co-authored 19 books focusing on Resistant Depression, OCD, PTSD and Neuroscience based Nomenclature (NbN), and was the founding associate editor of CNS Spectrums and of the World Journal of Biological Psychiatry.

Professor Zohar has been honored with several awards, including the Fogarty International Research Fellowship Award (1984), the A.E. Bennet Award for Clinical Research (1986 and 2002), ECNP Neuroscience Award for Clinical Research (1998), the WFSBP Award for Excellence in Education (2001), the Life Achievement Award by the Israeli Psychiatric Association (2018), Award for Clinicians-Researchers Collaboration Study in Psychiatry, by The Israel Society for Biological Psychiatry and The National Institute of Psychobiology in Israel (2019), and Mentor Award by Israel Society of Biological Psychiatry (2021).

Professor Zohar has received funding (RO1) from the National Institute of Mental Health (NIMH) to explore secondary prevention of PTSD (2012), from NATO (2018) to develop a guideline on the treatment in the ‘Golden Hours’ after a terror attack. He is also the Co-Chair of EU COST grant on Problematic Use of Internet PUI (2017), and USA Department of Defense (DoD) Grant (in collaboration with Mount Sinai hospital, NY) on Hydrocortisone, ‘Golden Hours’ and secondary prevention of PTSD (2019).